Developing scalable cell replacement therapies for the world

Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and has built collaborations with pioneers and leaders in the space. Our long-term vision is to create a scalable cell therapy platform to treat incurable diseases and democratize access to these newer technologies for the bottom 99 % of the population globally.

We have embedded manufacturing and quality processes in the platform which will enable us to create a virtuous cycle of innovation and decrease the time to market for such therapies. Our lead product out of the platform is Eyecyte-RPE aimed at treating Dry AMD (Age-related Macular Degeneration). Dry AMD is the largest cause of incurable blindness in people above 60 and affects roughly 170 million people worldwide. Pivotal efficacy and safety studies for this product have started at Oregon Health and Science University and we expect to begin first in man studies for the same in 2022.

Enroll in our Global Research Alliance

Recent Scientific Papers

Harshini Surendran, Saurabh Kumar, Swathi…

SARS-CoV-2 infection of human-induced pluripotent stem cells-derived lung lineage cells evokes inflammatory and chemosensory responses by targeting mitochondrial pathways

 23 April 2022

Konala VBR, Nandakumar S, Surendran…

Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies.

 Toxicol Appl Pharmacol. 2021;433:115792.

Nandakumar S, Shahani P, Datta…

Interventional Strategies for Parkinson Disease: Can Neural Precursor Cells Forge a Path Ahead?

 ACS Chem Neurosci. 2021;12(20):3785-3794.

Pal R

A small-molecule cocktail that beats cellular stress.

 Nat Methods. 2021;18(5):457-458

Battu R, Mallipatna A, Elackatt NJ, Schouten JSAG,

Webers Challenges of managing retinal dystrophies: an experience from south India. Ophthalmic Genetics.

2018. 39(1): 1-3.

Surendran H, Rathod RR. Pal R.

Generation of transplantable Retinal Pigmented Epithelial (RPE) cells for treatment of Age-related Macular Degeneration (AMD

2018. Meth Mol Biol. (Accepted).

Battu R, Mohan A, Khanna A, Kumar A, Shetty R

Retinal oxygen saturation in Retinitis Pigmentosa and macular dystrophies in Asian Indian eyes. Invest Ophthalmol Vis Sci. 2015.

56(5): 2798-802.

Battu R, Khanna A, Hegde B, Berendschot TT, Grover G, Schouten JS.

Correlation of Structure and Function of the Macula in patients with Retinitis Pigmentosa. Eye (Lond).

2015. 29(7): 895-901.
View all Scientific Papers

EyestemFollow

Eyestem
Retweet on TwitterEyestem Retweeted
Rajarshi Pal@RajarshiPal16·
5h

Great poster session with some interesting inputs and exciting conversations at the sidelines with stalwarts at an outstanding location...overall it was a fascinating experience representing @EyestemResearch and meeting ex-colleagues and friends at @ISSCR Boston! https://twitter.com/RajarshiPal16/status/1584445151178813440

2
Twitter 1596355388802465793
Eyestem@EyestemResearch·
10 Nov

Announcing our publication in @STARProtocols ! A patent-pending protocol to scale up manufacturing of Retinal Pigment Epithelium cells in collaboration with @CaseyEye . Proud of the amazing team of scientists at our company https://www.sciencedirect.com/science/article/pii/S2666166722006839?via%3Dihub

Twitter 1590547509071720458

Career Openings

View all